Applied Genetic Technologies Corporation

Informe acción NasdaqGM:AGTC

Capitalización de mercado: US$12.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Applied Genetic Technologies Dirección

Dirección controles de criterios 1/4

Información clave

Sue Washer

Chief Executive Officer (CEO)

US$1.5m

Compensación total

Porcentaje del salario del CEO37.38%
Permanencia del CEO20.7yrs
Participación del CEO0.2%
Permanencia media de la dirección1.4yrs
Promedio de permanencia en la Junta Directiva11.3yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Jul 26

AGTC receives positive feedback from FDA for manufacturing facility

Applied Genetic Technologies (NASDAQ:AGTC) said the U.S. Food and Drug Administration had provided favorable feedback on the current Good Manufacturing Practice (cGMP) design of AGTC’s manufacturing facility. The facility will support AGTC’s pipeline, including the late-stage development and potential commercialization of its eye diseases therapy like X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs. The company said initial operations at the facility are expected to begin in Q4 with GMP capabilities expected to be finalized in Q1 2023. "We expect the facility will also play an important role in support of our promising pipeline of additional clinical and pre-clinical programs," the company said. (AGTC) rose 1.3% premarket.
Seeking Alpha • Jul 12

Applied Genetic Technologies proposes stock offering to fund clinical trials

Applied Genetic Technologies (NASDAQ:AGTC) announced Tuesday it plans to initiate underwritten stock offering that will see the issue of its common shares and accompanying stock purchase warrants. The company intends to use the net proceeds for fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa program and its ongoing Phase 1/2 clinical trials in its Achromatopsia program, its preclinical development programs, investments in its manufacturing facility and for working capital and other general corporate purposes, including scheduled payments under its term loan with Hercules Capital, Inc. AGTC Shares fell 29% after-hours, Tuesday, to trade at $0.60. Earlier: Applied Genetic Technologies raised $9.8M in stock offering
Seeking Alpha • Jan 12

Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022

AGTC-501 is being developed to treat patients with X-linked retinitis pigmentosa. Two near-term results are expected in Q2 and Q3 of 2022, respectively; they are 3-month results from the SKYLINE study and 24-month results from the phase 1/2 study using AGTC-501. Results from two phase 1/2 studies pediatric patients with Achromatopsia are expected in Q1 of 2022. Applied Genetic Technologies Corporation had $90.5 million cash as of September 30, 2021; enough cash to fund its operations into 2023.
Seeking Alpha • Dec 14

An Assessment Of Applied Genetic Technologies Corporation

In the spotlight today is a developmental concern called Applied Genetic Technologies Corporation. The company has several gene therapy candidates in its pipeline and numerous potential milestones in 2022. A full investment analysis is provided in the paragraphs below.
Seeking Alpha • Jul 15

Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk

Applied Genetic Technologies Corporation is a mid-clinical-stage biotechnology company developing genetic therapies for rare and debilitating diseases. AGTC's initial focus is on ophthalmology (study of medical conditions relating to the eye) where AGTC has active programs for X-linked retinitis pigmentosa, achromatopsia, and optogenetics. AGT Corporation is in a reasonable financial position evidenced by 2+ years of cash runway driven by a low-cash burn (TTM: -$53M) and cash of $111M (March 2021). XLRP is being targeted by AGTC's lead therapeutic, RPGR, currently in a Phase 2/3 Vista study (data expected: 3Q 22) and a Phase 1/2 expansion trial known as Skyline (data expected: 4Q 21). In summary, the author projects Applied Genetic Technologies Corporation as a high-risk "hold".
Artículo de análisis • May 21

Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Artículo de análisis • Feb 05

What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?

Every investor in Applied Genetic Technologies Corporation ( NASDAQ:AGTC ) should be aware of the most powerful...
Artículo de análisis • Jan 06

Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Artículo de análisis • Dec 11

What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Sue Washer en comparación con los beneficios de Applied Genetic Technologies?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2022n/an/a

-US$70m

Jun 30 2022US$1mUS$551k

-US$69m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021n/an/a

-US$63m

Sep 30 2021n/an/a

-US$60m

Jun 30 2021US$1mUS$530k

-US$58m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020n/an/a

-US$57m

Sep 30 2020n/an/a

-US$50m

Jun 30 2020US$988kUS$530k

-US$46m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019n/an/a

-US$19m

Sep 30 2019n/an/a

-US$15m

Jun 30 2019US$1mUS$514k

-US$2m

Mar 31 2019n/an/a

US$2m

Dec 31 2018n/an/a

-US$18m

Sep 30 2018n/an/a

-US$19m

Jun 30 2018US$1mUS$502k

-US$21m

Mar 31 2018n/an/a

-US$18m

Dec 31 2017n/an/a

-US$11m

Sep 30 2017n/an/a

-US$4m

Jun 30 2017US$1mUS$487k

US$407k

Mar 31 2017n/an/a

US$6m

Dec 31 2016n/an/a

US$10m

Sep 30 2016n/an/a

US$11m

Jun 30 2016US$2mUS$464k

-US$1m

Compensación vs. Mercado: La compensación total de Sue($USD1.47M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD626.93K).

Compensación vs. Ingresos: La compensación de Sue ha aumentado mientras la empresa no es rentable.

CEO

Sue Washer (61 yo)

20.7yrs
Permanencia
US$1,473,567
Compensación

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Susan Washer
President20.7yrsUS$1.47m0.21%
$ 26.7k
Jonathan Lieber
Chief Financial Officer1.2yrsUS$1.00msin datos
Susan Schneider
Chief Medical Officer1yrUS$832.63ksin datos
Nicholas Muzyczka
Co-Founder23.8yrssin datossin datos
Barry Byrne
Co-Founder23.8yrssin datossin datos
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno datasin datossin datos
Richard Samulski
Co-Founder23.8yrssin datossin datos
Terence Flotte
Co-Founder23.8yrssin datossin datos
Gerald Reynolds
Chief Accounting Officer1.4yrssin datos0.013%
$ 1.6k
Abraham Scaria
Chief Scientific Officerless than a yearsin datossin datos
Hope D'Oyley-Gay
General Counselless than a yearsin datossin datos
David Knop
Senior Vice President of Process & Assay Developmentless than a yearUS$141.25ksin datos
1.4yrs
Permanencia media
57yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de AGTC no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Susan Washer
President19yrsUS$1.47m0.21%
$ 26.7k
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno datasin datossin datos
Edward Hurwitz
Independent Director10yrsUS$65.23k0.041%
$ 5.1k
Anne VanLent
Independent Director6.3yrsUS$79.23ksin datos
Scott Koenig
Independent Chairman of the Board20.6yrsUS$101.50k0.051%
$ 6.4k
David Birch
Member of Ophthalmology Scientific Advisory Boardno datasin datossin datos
William Aliski
Independent Director4.2yrsUS$78.23k0.013%
$ 1.6k
Peter Campochiaro
Member of Ophthalmology Scientific Advisory Boardno datasin datossin datos
James Rosen
Independent Director12.7yrsUS$72.34k0.0015%
$ 186.7
Paul Kaufman
Member of Ophthalmology Scientific Advisory Boardno datasin datossin datos
Stephen Daiger
Member of Ophthalmology Scientific Advisory Boardno datasin datossin datos
Robert Molday
Member of Ophthalmology Scientific Advisory Boardno datasin datossin datos
11.3yrs
Permanencia media
65.5yo
Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de AGTC son experimentados ( 11.3 años antigüedad media).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2022/12/01 13:06
Precio de las acciones al final del día2022/11/30 00:00
Beneficios2022/09/30
Ingresos anuales2022/06/30

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Applied Genetic Technologies Corporation está cubierta por 10 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
James BirchenoughBMO Capital Markets Equity Research
Yun ZhongBrean Capital Historical (Janney Montgomery)
Yun ZhongBTIG